---
title: "Pre-market hot trades in US stocks: Quantum Biopharma up 7.64% in pre-market; GSK down 7.10% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284571712.md"
description: "Quantum Biopharma pre-market up 7.64%; GSK pre-market down 7.10%; Inno pre-market up 68.88%; Sagtec Global pre-market up 61.16%; Rising Dragon Acquisition pre-market up 44.29%"
datetime: "2026-04-29T12:27:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284571712.md)
  - [en](https://longbridge.com/en/news/284571712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284571712.md)
---

# Pre-market hot trades in US stocks: Quantum Biopharma up 7.64% in pre-market; GSK down 7.10% in pre-market

**Pre-market Hot Trades in US Stocks**

Quantum Biopharma is up 7.64% in pre-market trading. Based on recent key news:

1.  On April 28, Quantum Biopharma issued a statement emphasizing that its forward-looking statements may change, and investors should exercise caution. This statement may trigger market attention on the company's future development, driving the stock price up.
    
2.  On April 28, SAS plans to launch quantum artificial intelligence products at the SAS Innovate event in Dallas. The stability of the quantum hardware supply chain makes the technology applicable in various industries, which may positively impact Quantum Biopharma's market positioning.
    
3.  There are no other significant news recently. The application prospects of quantum technology are broad, and market attention is high.
    

GSK is down 7.10% in pre-market trading. Based on recent key news:

1.  On April 29, GSK announced its first-quarter financial report, with revenue of £7.63 billion, exceeding market expectations. Despite strong performance, the market was disappointed by the lack of an upgraded full-year guidance, leading to a decline in stock price. Source: Zhitong Finance
    
2.  On April 29, GSK announced a quarterly dividend reduction of 5.6% to 17 pence per share. This news may raise investor concerns about the company's future cash flow, further pressuring the stock price. Source: RTT News
    
3.  On April 29, analysts pointed out that although GSK's earnings exceeded expectations, the market's negative reaction may be due to insufficient investor confidence in the company's future growth. Source: WSJ The pharmaceutical company faces risks from changes in US drug pricing policies.
    

**Top Gainers in Pre-market US Stocks**

Inno is up 68.88% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Sagte Global is up 61.16% in pre-market trading. Based on recent key news:

1.  On April 29, Sagte Global reported record revenue of $19.1 million for the fiscal year 2025, a 49% year-over-year increase. This strong financial performance drove a significant rise in stock price. Source: Sagte Global Limited
    
2.  On April 29, Sagte Global issued a forward-looking statement regarding future growth prospects, AI platform adoption, and market expansion. Despite risks and uncertainties, these positive expectations enhanced investor confidence, further driving the stock price up. Source: Sagte Global Limited
    
3.  On April 28, Sagte Global corrected the date errors for the financial report release and conference call, ensuring investors correctly mark the dates. This clarification helped stabilize market expectations. Source: Sagte Global Limited The technology industry is experiencing strong growth, with significant capital inflows Rising Dragon Acquisition, pre-market up 44.29%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### Related Stocks

- [QNTM.US](https://longbridge.com/en/quote/QNTM.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [INHD.US](https://longbridge.com/en/quote/INHD.US.md)
- [SAGT.US](https://longbridge.com/en/quote/SAGT.US.md)
- [RDAC.US](https://longbridge.com/en/quote/RDAC.US.md)

## Related News & Research

- [GSK (LON:GSK) Insider Purchases £130.62 in Stock](https://longbridge.com/en/news/286511281.md)
- [GSK: Japan's MHLW Expands Eligible Population For Arexvy](https://longbridge.com/en/news/286723820.md)
- [GSK executives acquire shares under company reward plan](https://longbridge.com/en/news/286434027.md)
- [GSK Launches Final GBP 0.18 Bln Tranche Of GBP 2 Bln Share Buyback](https://longbridge.com/en/news/285899627.md)
- [GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks](https://longbridge.com/en/news/285980824.md)